Pharmaxis Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Pharmaxis Ltd with three other
companies in this sector in Australia:
Clinuvel Pharmaceuticals Limited
sales of 17.03 million Australian Dollars [US$13.47 million]
of which 100%
(18.61 million Australian Dollars [US$14.72 million]
of which 88%
was Drug discovery and development), and
Xrf Scientific Ltd
(21.54 million Australian Dollars [US$17.04 million]
of which 40%
was Precious Metals).
During the year ended June of 2017, sales at
Pharmaxis Ltd were A$17.64 million (US$13.95 million).
decrease of 5.0%
versus 2016, when the company's sales were A$18.57 million.
Contributing to the drop in overall sales was the 9.2% decline
in Bronchitol and Aridol, from A$14.91 million to A$13.54 million.
However, these declines were partially offset by the increase in sales of
New Drug Development (up 32.4% to A$3.42 million)
Corporate (up 6.3% to A$337,000.00 )